Loading
The Oxford oncologist who led QUASAR 2 and co-led SCOT, the trial that cut adjuvant chemotherapy for bowel cancer from six months to three without losing benefit.
Rachel Kerr is a medical oncologist and Associate Professor of Gastrointestinal Oncology in the University of Oxford's Department of Oncology, works at Oxford University Hospitals NHS Trust within the colorectal cancer multidisciplinary team, and is clinical director of phase 3 trials at the Oncology Clinical Trials Office. She was first author of QUASAR 2, which showed that adding bevacizumab to adjuvant capecitabine did not improve disease-free survival, and second author of SCOT, which found three months of adjuvant oxaliplatin-fluoropyrimidine chemotherapy non-inferior to six months with far less lasting peripheral neuropathy.
Shares Tim Maughan, CAPOX (capecitabine, oxaliplatin), Colorectal cancer and the tags colorectal, trialist, uk.
Shares Tim Maughan, Oxford Cancer (Oxford University Hospitals and University of Oxford), CAPOX (capecitabine, oxaliplatin), Oxaliplatin and the tags colorectal, uk.
Shares Colorectal cancer and the tags colorectal, trialist, uk.
Shares Colorectal cancer and the tags colorectal, trialist, uk.
Shares Colorectal cancer and the tags colorectal, trialist, uk.
Shares Colorectal cancer and the tags colorectal, trialist, uk.
Shares Colorectal cancer and the tags colorectal, trialist.
Shares SCOT, CAPOX (capecitabine, oxaliplatin), Oxaliplatin, Capecitabine.